Las Palmas, Spain (May 2019) – Based on its recent analysis of the European sports nutrition and health ingredients market, Frost & Sullivan recognises Spain-based Nektium Pharma with the “2019 European New Product Innovation Award” for its already award winning novel natural botanical extract, Zynamite®.
This product has demonstrated significant ergogenic and nootropic properties including faster reaction time and better mental and physical performance. It is a safe, doping free and sustainable alternative to caffeine, with nutritional benefits that are superior to those of competing natural extracts.
“Nektium launched the novel, patent-pending Mangifera indica extract, Zynamite®, which is derived from mango leaves and composed of 60% mangiferin, a xanthone. It has been shown to have ergogenic and nootropic properties that enable early mental activation; better mental and physical performance; and dramatic increases in peak power, mean power output, VO2max, muscle oxygen utilisation, and brain oxygenation. It is also an inhibitor of catechol-O-methyltransferase, or COMT, which has anti-addictive potential,” said Smriti Sharma, industry analyst. “While other companies too have developed novel herbal or plant-based nootropic agents, none offer the combination of benefits that Zynamite® does.”
Its strong patent portfolio, with three pending patents for different attributes of the mangiferin extract, protects its first-mover advantage. Nektium showed that the activation mechanism of Zynamite® on the central nervous system is different to that of caffeine but with a surprisingly similar effect, which gives it an edge over other key natural extracts. Furthermore, unlike caffeine, Zynamite® has shown no negative side effects among users.
“We are delighted to receive yet another award for Zynamite® this year. We have already received the Nutraingredients Award in May for the Best Research Project on Zynamite® and in 2018 Zynamite® won in the category Ingredient of the Year: Sports Nutrition. I am proud of our dedicated R&D team for bringing such a great innovation to the market place and I am happy that it is already receiving recognition in its first year of sales. I was very impressed by the intensive research Frost & Sullivan did on our work and happy that they have chosen Zynamite®!”, says Miguel Jiménez, owner and CEO of Nektium.
Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognises the value-added features/benefits of the product and the faster return on investment it gives to the customers, which, in turn, raises customer acquisition and overall market penetration potential.
For more information: https://best-practices.frost-multimedia-wire.com/nektiumpharma